Women reaching equality in health, despite the differences Nowadays women remain the largest CAD population subgroup being under-diagnosed and under-treated.

Slides:



Advertisements
Similar presentations
Choctaw Nation Diabetes Wellness Center
Advertisements

Women’s Heart Policy October, 2004 Gastein John O’Toole (personal capacity) Perm Rep of Irl to EU.
Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.
Can we prevent stent restenosis after coronary stent implantation
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
1 Women & Heart Disease Julia C. Orri, Ph.D. Biol. 330 November 21, 2006.
Breast Cancer Awareness October is Breast Cancer Awareness Month Submitted by Kadee Brousseau, Peer Advisor, University of Missouri.
EVIDENCE BASED MEDICINE
Successful Approaches to Reduce Hypertension Stephen Sidney, MD, MPH Kaiser Permanente Northern California October 17, 2012.
Women and Heart Disease: Triage Criteria Symptoms versus Reality.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation? July
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Health Status of Australian Adults. The health status of Australians is recognised as good and is continually improving. The life expectancy for males.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Health Disparities of Minority Women and Diabetes Kathleen M. Rayman, Ph.D., RN Appalachian Center for Translational Research in Disparities Faculty Development.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Management of Stable Angina SIGN 96
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
European Society of Cardiology Cardiovascular diseases in women.
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Saudi Diploma in Family Medicine / 24 1 Dr. Zekeriya Aktürk Preventive Medicine and Periodic Health Examinations in Primary Care.
Acute Stroke: Principles of Modern Management A program of the American Academy of Neurology The AAN Acute Stroke Management courses are supported in part.
9-1-1 COORDINATION WORKGROUP Samar Muzaffar, MD MPH.
Time Critical Diagnosis Rural-Urban Workgroup Samar Muzaffar, MD MPH.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Group 7 Burden of disease in Brazil. KEY HEALTH INDICATORS Years of life lost (YLLs): Years of life lost due to premature mortality. Years lived with.
Female Gender Is An Independent Predictor Of In-Hospital Mortality After STEMI In The Era of Primary PCI. Insights From The Greater Paris Area PCI Registry.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Long-term mortality after acute stroke  Stroke is a leading cause of mortality: 6 million fatal events annually worldwide.  Mainly affects elderly, but.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
American Heart Association. Available at Accessed February
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
European Heart Health Charter Official Launch 12 June 2007 European Parliament - Brussels "Every child born in the new millennium has the right to live.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Inter-Hospital Transfer of High Risk STEMI Patients for PCI is Safe and Feasible David M. Larson, Katie M. Menssen, Scott W. Sharkey, Marc C. Newell, Anil.
4S: Scandinavian Simvastatin Survival Study
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Door to Balloon Time: Does it Matter? Tale of Two Studies.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
Breast cancer facts Daniela Cazares. Fact #1 In the US, 1 in 8 women will be diagnosed with breast cancer in their lifetime.
Cardiovascular Disease Prevention Know, Understand, and Act University of Ottawa Heart Institute Division of Prevention & Rehabilitation.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
The Natural History of Benign Thyroid Nodules JAMA. 2015;313(9): doi: /jama Modulator Prof. 전숙 / R1 윤수진.
Associate Professor, Honorary Consultant Cardiologist
Prof Kim Myeong Kon / R1 Park Ji Yoon
American Heart Month Resources:
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Patient populations by study group figure 10
HOPE: Heart Outcomes Prevention Evaluation study
Jane E Scullion Respiratory Nurse Consultant
 Gender based differences in the presentation, treatment and outcome of Acute Coronary Syndrome patients : insights from the Himachal Pradesh ACS-registry.
Trends in Coronary Procedures per 1000 Medicare Beneficiaries
Chapter 1 Benefits and Risks Associated with Physical Activity
How and When to Decide on Revascularization in Stable Ischemic Heart Disease.
European Heart Association Journal 2007 April
Dr. PJ Devereaux on behalf of POISE Investigators
American Heart Association Presented by Dr. Julinda Mehilli
LRC-CPPT and MRFIT Content Points:
Presentation transcript:

Women reaching equality in health, despite the differences Nowadays women remain the largest CAD population subgroup being under-diagnosed and under-treated despite having the highest risk of mortality and morbidity from CAD.

Facts About Heart Disease in Women Cardiovascular disease is the No. 1 killer of women in the world, causing 1 in 3 deaths each year. In 2012 cardiovascular disease caused deaths in women in the world. That represents deaths per month and deaths daily. In Europe Cardiovascular disease remains the most common cause of death in women and is responsible for 49% of all deaths, almost 1 in 2 deaths each year. Each year 2 million women die in Europe from cardiovascular disease. That represents deaths per month and deaths daily. Almost 4 european women die every minute! Coronary heart disease is the most common single cause of death in women, 10 times more frequently than mortality from breast cancer 20% vs 2%. Almost 1 million women die in Europe from coronary heart disease.

1- Differences In the increasingly ageing population of Europe, women account for the majority of the older citizens. Physical differences exist between the underlying biology in women’s vascular beds compared to those of men. These physical differences may partly justify the increased mortality of women with cardiovascular disease. This excesive mortality observed in women may be due to factors other than physical differences.

2- Lack of equality, causes. Lack of awareness towards ischemic symptoms is one of the most important reasons for delayed presentation in women Late presentation in the clinic is associated with delayed diagnosis and therapeutic procedures The later treatment is performed from symptom onset less myocardial salvage is carried out. Time interval from symptom onset to first physician contact is at least one and half hours longer in women than in men.

3-Lack of equality, reality Women experience delays in identification of the STEMI diagnosis and also in the PCI process. Door to balloon time is higher in women than men. Women are less revascularized under the guideline- recommended time compared to men. This occours mainly during off hours.

3- Lack of equality, reality Cardiac rehabilitation programmes are shown to reduce recurrent cardiac events and related premature death in patients with cardiovascular diseases. Women are significantly underrepresented in cardiac rehabilitation programs with less referral and less completion. It is known when women complete programs, they experience the greatest reduction in mortality compared to men.

4- Lack of equality, results Women undergoing PCI for STEMI have higher mortality than men. Mortality at 1-year follow-up :15.1% vs. 9.3%. Mortality at 4-year follow-up:21.6% vs. 15.0% This excess of mortality could only partially be explained by their physical differences and baseline characteristics.

In order to reduce this lack of equality we should increase awareness about cardiovascular disease in women as well as in men. Increase awareness about cardiovascular disease in women is mandatory in the health community : diagnosis, treatment and referral to Cardiac rehabilitation programmes must achieve equality.